Oxford Biotherapeutics
Oxford, UK and San Jose, CA, 22 July 2024 – Oxford BioTherapeutics (OBT), a clinical-stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate (ADC) based therapies, has announced that it has been named “Tech Small Business of the Year” at the sixth annual Thames Valley Tech & Innovation Awards 2024. These awards celebrate the achievements of leading, diverse companies across the region.
OBT was selected as the recipient in recognition of its outstanding achievements in innovation, scientific excellence and commitment to improving patient outcomes, as well as its position as an industry leader and significant progress as a major player in the ADC and T-cell derivation fields.
The Tech Small Business of the Year Award recognizes outstanding utilization of technology to advance company goals, improve communities, and/or empower customers. OBT received this award for its continued commitment and application of cutting-edge technological approaches, including the implementation of enhanced proprietary OGAP®-Verify, mass spectrometry, and analytical biochemistry, to develop novel therapeutics to treat unmet needs in cancer. Notably, OBT’s proprietary clinical assets are leveraged through the OGAP® discovery platform, and collaborations leveraging this platform have resulted in many fruitful partnerships with industry leaders, further demonstrating the strength and versatility of target discovery technology.
Dr Christian Rohrf, CEO, said: “We are incredibly honoured to have been named Tech SME of the Year at the Thames Valley Tech & Innovation Awards. This award is testament to the hard work and dedication of all the teams at OBT who are committed to developing innovative therapies for cancer treatment. This year’s win highlights the significant technological advancements made in our discovery database, OGAP®-Verify, which aims to improve the success rate of cancer treatment. This honour inspires us to continue in our mission of driving innovation and excellence for cancer patients.”
Last year, OBT won the ‘Tech Company of the Year’ and ‘Special Recognition’ awards at the annual Thames Valley SME Growth 100 Awards, further cementing its reputation as a pioneer and leader in technology innovation in the region.
xxx
About Oxford Biotherapeutics
Oxford BioTherapeutics (OBT) is a clinical-stage oncology company with a pipeline of best-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to meet unmet patient needs in cancer treatment, including bispecific, chimeric antigen receptor T cell (CAR-T), antibody-drug conjugate (ADC) and antibody-dependent cell-mediated cytotoxicity (ADCC) therapeutics.
The story continues
OBT’s lead clinical program, OBT076, began expanding U.S. clinical trials in patients with advanced or refractory solid tumors overexpressing CD205, including gastric, bladder, ovarian and lung cancer, in 2021. Tumor infiltration by immune suppressive cells correlates with adverse outcomes (reduced progression-free and overall survival), suggesting that this process contributes to the progression of several cancers.
OBT’s proprietary OGAP®-Verify target discovery platform is based on one of the largest proprietary cancer membrane proteome databases in the world, providing unique and highly qualified tumor targets with data on over 5,000 cancer cell proteins, three of which are in clinical development in the U.S. and Europe. OBT’s IO discovery process has provided unique insights into the cancer-immune cell synapse and has identified several novel IO monoclonal and bispecific antibody candidates for cancer therapy.
OBT’s pipeline and development capabilities are demonstrated through multiple strategic partnerships, including cell therapy research collaborations with Boehringer Ingelheim, Immunogen and Kite Pharma, as well as other global leaders in antibody development, including Amgen, WuXi, Medarex (BMS), Alere (Abbott) and BioWa. OBT has a strong oncology-focused management team and board of directors with extensive experience in the development of IO and antibody-based therapeutics.
For more information about Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com or follow us on LinkedIn.
Investor:
CEO Dr. Christian Rolf
christian.r@oxfordbiotherapeutics.com
media:
Medistrava
Sylvie Berebi, Sandy Greenwood, Erica Hollingsworth
Email: OBT@medistrava.com
Phone: +44 (0)203 928 6900
